File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions
  • Basic View
  • Metadata View
  • XML View
TitleChronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions
 
AuthorsAhn, SH6
Chan, HLY7
Chen, PJ8
Cheng, J11
Goenka, MK12
Hou, J1
Lim, SG9
Omata, M10
Piratvisuth, T2
Xie, Q4
Yim, HJ5
Yuen, MF3
 
KeywordsALT
Chronic hepatitis B (CHB)
HBV DNA
Hepatitis B virus (HBV)
Interferon alfa
Nucleoside/nucleotide analog
 
Issue Date2010
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
CitationHepatology International, 2010, v. 4 n. 1, p. 386-395 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9163-9
 
AbstractRecent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. © 2010 Asian Pacific Association for the Study of the Liver.
 
DescriptionContributed by the APPROACH Working Group
 
ISSN1936-0533
2012 Impact Factor: 2.642
2012 SCImago Journal Rankings: 0.775
 
DOIhttp://dx.doi.org/10.1007/s12072-010-9163-9
 
PubMed Central IDPMC2836441
 
ISI Accession Number IDWOS:000275456400003
Funding AgencyGrant Number
Bristol-Myers Squibb
Funding Information:

Bristol-Myers Squibb provided an unrestricted educational grant to accredited medical education provider, Adrenalin Strategics (Australia), for management of the APPROACH Working Group meeting. Editorial support for the development of this report was provided by Adrenalin Strategics (Australia) and MediTech Media (Singapore).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorAhn, SH
 
dc.contributor.authorChan, HLY
 
dc.contributor.authorChen, PJ
 
dc.contributor.authorCheng, J
 
dc.contributor.authorGoenka, MK
 
dc.contributor.authorHou, J
 
dc.contributor.authorLim, SG
 
dc.contributor.authorOmata, M
 
dc.contributor.authorPiratvisuth, T
 
dc.contributor.authorXie, Q
 
dc.contributor.authorYim, HJ
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2012-02-21T05:44:53Z
 
dc.date.available2012-02-21T05:44:53Z
 
dc.date.issued2010
 
dc.description.abstractRecent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. © 2010 Asian Pacific Association for the Study of the Liver.
 
dc.description.naturepublished_or_final_version
 
dc.descriptionContributed by the APPROACH Working Group
 
dc.description.otherSpringer Open Choice, 21 Feb 2012
 
dc.identifier.citationHepatology International, 2010, v. 4 n. 1, p. 386-395 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9163-9
 
dc.identifier.citeulike6802838
 
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-010-9163-9
 
dc.identifier.eissn1936-0541
 
dc.identifier.epage395
 
dc.identifier.isiWOS:000275456400003
Funding AgencyGrant Number
Bristol-Myers Squibb
Funding Information:

Bristol-Myers Squibb provided an unrestricted educational grant to accredited medical education provider, Adrenalin Strategics (Australia), for management of the APPROACH Working Group meeting. Editorial support for the development of this report was provided by Adrenalin Strategics (Australia) and MediTech Media (Singapore).

 
dc.identifier.issn1936-0533
2012 Impact Factor: 2.642
2012 SCImago Journal Rankings: 0.775
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2836441
 
dc.identifier.pmid20305758
 
dc.identifier.scopuseid_2-s2.0-77949655951
 
dc.identifier.spage386
 
dc.identifier.urihttp://hdl.handle.net/10722/144957
 
dc.identifier.volume4
 
dc.languageEng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology International
 
dc.relation.referencesReferences in Scopus
 
dc.rightsAsian Pacific Association for the Study of the Liver
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subjectALT
 
dc.subjectChronic hepatitis B (CHB)
 
dc.subjectHBV DNA
 
dc.subjectHepatitis B virus (HBV)
 
dc.subjectInterferon alfa
 
dc.subjectNucleoside/nucleotide analog
 
dc.titleChronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ahn, SH</contributor.author>
<contributor.author>Chan, HLY</contributor.author>
<contributor.author>Chen, PJ</contributor.author>
<contributor.author>Cheng, J</contributor.author>
<contributor.author>Goenka, MK</contributor.author>
<contributor.author>Hou, J</contributor.author>
<contributor.author>Lim, SG</contributor.author>
<contributor.author>Omata, M</contributor.author>
<contributor.author>Piratvisuth, T</contributor.author>
<contributor.author>Xie, Q</contributor.author>
<contributor.author>Yim, HJ</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2012-02-21T05:44:53Z</date.accessioned>
<date.available>2012-02-21T05:44:53Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Hepatology International, 2010, v. 4 n. 1, p. 386-395</identifier.citation>
<identifier.issn>1936-0533</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/144957</identifier.uri>
<description>Contributed by the APPROACH Working Group</description>
<description.abstract>Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the &quot;Asian-Pacific consensus statement on the management of chronic hepatitis B&quot; offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. &#169; 2010 Asian Pacific Association for the Study of the Liver.</description.abstract>
<language>Eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0</publisher>
<relation.ispartof>Hepatology International</relation.ispartof>
<rights>Asian Pacific Association for the Study of the Liver</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>ALT</subject>
<subject>Chronic hepatitis B (CHB)</subject>
<subject>HBV DNA</subject>
<subject>Hepatitis B virus (HBV)</subject>
<subject>Interferon alfa</subject>
<subject>Nucleoside/nucleotide analog</subject>
<title>Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4551/resserv?sid=springerlink&amp;genre=article&amp;atitle=Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions&amp;title=Hepatology International&amp;issn=19360533&amp;date=2010-03-01&amp;volume=4&amp;issue=1&amp; spage=386&amp;authors=Sang Hoon Ahn, Henry L. Y. Chan, Pei-Jer Chen, &lt;i&gt;et al.&lt;/i&gt;</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1007/s12072-010-9163-9</identifier.doi>
<identifier.pmid>20305758</identifier.pmid>
<identifier.pmcid>PMC2836441</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-77949655951</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77949655951&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>4</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>386</identifier.spage>
<identifier.epage>395</identifier.epage>
<identifier.eissn>1936-0541</identifier.eissn>
<identifier.isi>WOS:000275456400003</identifier.isi>
<publisher.place>United States</publisher.place>
<description.other>Springer Open Choice, 21 Feb 2012</description.other>
<identifier.citeulike>6802838</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/144957/1/12072_2010_Article_9163.pdf</bitstream.url>
</item>
Author Affiliations
  1. Southern Medical University
  2. Prince of Songkla University
  3. The University of Hong Kong
  4. Shanghai Jiaotong University
  5. Korea University Medical Center
  6. Yonsei University College of Medicine
  7. Prince of Wales Hospital Hong Kong
  8. National Taiwan University Hospital
  9. National University of Singapore
  10. University of Tokyo
  11. Capital Medical University China
  12. Institute of Gastroenterology and Endoscopy